While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or «bad» cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of heart disease risk.
Experimental siRNA therapeutic shows promise to reduce an important driver of heart disease risk
While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or "bad" cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of heart disease risk.